Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Shareholder Meeting (September 2015)
27 slides from Viyash Scientific's shareholder meeting presentation, Sep 24, 2015
Slide 1: Warm Welcome to our Shareholders
LIVING Seauent THE VISION Warm Welcome to our Shareholders September 24,2015
Slide 2: Sequence of Events
SeQuence of Events Seouent « Strategic Decision and Actions * Performance in FY 15 " Key Initiatives for FY 16 » Agenda of AGM
Slide 3: Strategic Decision and Actions
STRATEGIC DECISION AND ACTIONS
Slide 4: Year in Retrospect
Year in Retrospect Seouent Strategy laid in FY14: ‘To become a power-house in the Global Animal Health business with a portfolio of niche human APIs’ Steps: 1. Create a valuable, independent, integrated, global Animal health business (Business brought under “Alivira’) 2. Accelerate growth in Human A
Slide 5: Animal Healthcare
Animal Healthcare Seouent Strategy - Create a valuable, independent, integrated and global animal health business ALIVIRA Action Commissioned our new API facility at Vizag to cater regulated markets Acquired Provet, Turkey’s 3 largest animal health formulations company to strengthen our presence in
Slide 6: Human APIs
Human APIs Seouent Strategy - Accelerate growth in Human Health API with focus on niche molecules Action Human Health APIs segment registered 21%+ growth Increased the capacity in our Mangalore facility and acquired adjacent land for future expansion Long-term non-exclusive, royalty-free licensing a
Slide 7: Exit Non strategic business
Exit Non strategic business Seauent Strategy — To Exit businesses which are not strategic to core business Action Closed down our operations in Vietnam and Kenya Completed the divestment of our specialty chemicals division to Songwon Industrial Group in August 2014 Post the commercialisation of faci
Slide 8: Research and Development
Research and Development Seouent Strategy - Enhance our efforts in Research and Development (R&D) Action * Reengineered the R&D function for both scale and scope ¢ Accelerated our efforts in ongoing projects to fast track new product introductions ¢ Introduced 30+ APIs across Human and Animal Health
Slide 9: Analytical Services
ANALYTICAL SERVICES
Slide 10: Scale up of analytical services
Scale up of analytical services Seaquent Strategy - Scale up of Analytical Services(SRL) Action Expanded our analytical and bioanalytical services to new customers and geographic segments Improved our client serviceability through new proposed centres closer to client geographies Increased scope of
Slide 11: To Sum up...
; To Sum up... Seouent ALIVIRA = Westrengthened the prominence of Alivira, our animal health brand " Today, we have a stronger integrated platform (Animal Health API and formulations) HUMAN APIs = We expedited our growth in Human Health API with focus on new niche molecules RESEARCH AND DEVELOPMENT
Slide 12: Performance in FY15
J PERFORMANCE IN FY15
Slide 13: Financial Indicators (Consolidated)
Financial Indicators(Consolidated) Seauent O Proven Ability In Life Sciences Figures in INR mn Consolidated Revenues Post Tax Profit/(Loss) 4,654 FY11 FY12 FY13 FY14 FY15 = ~~ |_| (40) (15) (118) (647) FYIS (1,105) Significant reduction in losses in FY15 13
Slide 14: Abstract from Consolidated P&L Account
Abstract from Consolidated P&L Account Seouent PARTICULARS FY14 FY15 Revenue from Operations 4,555 4,654 Operating Expenses 1,648 2,037 ADJUSTED EBITDA 486 205 % 11% 4% Finance Cost (390) (445) Profit before Exceptional Items (192) (469) Exceptional Items (907) 385 ®Taxes - (6) (34) Earnings After T
Slide 15: Consolidated Balance Sheet
Consolidated Balance Sheet Seauent e PARTICULARS FY14 FY15 LIABILITIES Equity and Reserves 281 625 Share Application Money 287 288 Borrowings - Banks 2,646 3,733 Borrowings - Promoters/Group 1538 1,016 Minority Interest 45 1,469 Provisions/Other Liabilities 1,430 1,946 TOTAL 6,227 9,077 ASSETS Fixed
Slide 16: Market Capitalization
Market Capitalization Seaquent O Proven Ability In Life Sciences Stock price movement 945 82 190 Mar 31,2011 Mar31,2012 Mar31,2013 Mar31,2014 Mar31,2015 June30,2015 Sep1é6,2015 Market Cap(mn) 38934 ~ Mar 31,2011 Mar31,2012 Mar31,2013 Mar31,2014 + Mar31,2015 ‘June 30,2015 Sep 16, 2015
Slide 17: Post Balance Sheet events: Fund Raising Through QIP
Post Balance Sheet events Seouent Fund Raising Through QIP " Issued 7,476,635 equity shares at Rs. 535 per share aggregating to INR 4,000 mn " The QIP proceeds will be utilized to meet our long term funding requirements including investments in R&D and new markets, capital expenditure and to meet th
Slide 18: Post Balance Sheet events: Q1 FY Results
Post Balance Sheet events Seouent Q1 FY 16 Results Financial Performance =" Operating revenue was Rs 1484 mn as compared to Rs 1127 mn in QIFY15, up by 32% = Continuing operations* grew by 45% over QIFY15 = EBITDA at Rs 188 mn as compared to Rs.74 mn in QIFY15 = EBITDA Margin at 12.7% for QIFY16 as
Slide 19: Acquisition of Animal Health Business of Lyka
Post Balance Sheet events Seouent Acquisition of Animal Health Business of Lyka « Alivira and Lyka Exports Limited (Lyka) , a Subsidiary of Lyka Labs Limited, have entered into a definitive agreement under which Alivira will acquire the Animal Health Business of Lyka on a “going concern’ basis = Acq
Slide 20: New analytical centre at Bengaluru
Post Balance Sheet events Seouent New analytical centre at Bengaluru (SRL) In line with the strategic plan to add new centres for improved client serviceability. Built with a laboratory space of 10,000 square feet and latest analytical equipment Through our new centre, we have expanded our business
Slide 21: Ratings Upgraded (ICRA) for SeQuent
Post Balance Sheet events Seouent Ratings Upgraded (ICRA) for SeQuent = The Long term rating has been upgraded from ICRA BB(Double B) to ICRA BBBH(Triple B Plus) . The Outlook on the long term rating is stable " The Short term rating has been upgraded from ICRA A4+(A four plus) to ICRA A2+(A two plu
Slide 22: Key Initiatives for FY16
KEY INITIATIVES FOR FY 16
Slide 23: Consolidation of Alivira Holdings
Consolidation of Alivira Holdings Seaquent The Board of Directors of the Company at its meeting held on June 30, 2015 approved the following: " Consolidation of shareholding in Alivira by acquiring all the shares(9,997,941 shares) held in Alivira from Ascent Capital and Devicam Capital " Oncompletio
Slide 24: Business Priorities - FY16
Business Priorities- FY 16 Seouent Alivira = Expanding geographical footprint and capabilities both through inorganic and organic initiatives largely in Animal Health Formulations space = Focus on value creation in Animal health API business through price increase initiatives and higher share of bus
Slide 25: Agenda for AGM
AGENDA FOR AGM
Slide 26: Agenda for AGM
Agenda for AGM Seouent Adoption of Financial results for FY15 Appointment of Director in place of Mr. Kannan Ramanujam Ratification of appointment of statutory auditors Appointment of Mr. Narendra Mairpady as an Independent Director Remuneration of Cost Auditors for FY 16 Approve related party trans
Slide 27: Thank You
Seauent Proven Ability In Life Sciences Thank You
SeQuent Scientific — Shareholder Meeting (September 2015) on 6ix